Advertisement
Screener

Ovid Therapeutics Inc. (OVID) Investing Cash Flow

1.9 / 5 stars · 25/65 Roast Me

Ovid Therapeutics Inc. Investing Cash Flow

Ovid Therapeutics Inc. (OVID) reported Investing Cash Flow of -$80.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-13

  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$86.74M, a 819.65% decline year-over-year.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $5.95M, a 16.62% increase year-over-year.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$72.06M, a 438.45% decline year-over-year.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $5.05M, a 1630.48% increase year-over-year.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$49.85M, a 191.32% decline from fiscal 2024.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2024 was $54.59M.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$2.58M.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$87.88M.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 3 month as first filedNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 6 month as first filedNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 9 month as first filedNet Cash Provided by (Used in) Investing Activities 12 monthNet Cash Provided by (Used in) Investing Activities 12 month as first filed
2026-06-30-$86.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$80.79M
10-Q · filed 2026-08-13
-$152.85M
derived: sum of 3 quarters · filed 2026-08-13
-$147.80M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$5.95M
10-Q · filed 2026-05-12
-$66.11M
derived: sum of 2 quarters · filed 2026-05-12
-$61.06M
derived: sum of 3 quarters · filed 2026-05-12
-$49.01M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31-$72.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
-$67.01M
derived: sum of 2 quarters · filed 2026-03-18
-$54.96M
derived: sum of 3 quarters · filed 2026-08-13
-$49.85M
10-K · filed 2026-03-18
2025-09-30$5.05M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$17.11M
derived: sum of 2 quarters · filed 2026-08-13
$22.21M
10-Q · filed 2025-11-12
$43.50M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$12.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$17.16M
10-Q · filed 2026-08-13
$38.45M
derived: sum of 3 quarters · filed 2026-08-13
$38.74M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$5.10M
10-Q · filed 2026-05-12
$26.39M
derived: sum of 2 quarters · filed 2026-05-12
$26.69M
derived: sum of 3 quarters · filed 2026-05-12
$39.51M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31$21.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$21.58M
derived: sum of 2 quarters · filed 2026-03-18
$34.41M
derived: sum of 3 quarters · filed 2026-03-18
$54.59M
10-K · filed 2026-03-18
2024-09-30$292.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$13.11M
derived: sum of 2 quarters · filed 2025-11-12
$33.30M
10-Q · filed 2025-11-12
-$15.21M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$12.82M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
$33.01M
10-Q · filed 2025-08-13
-$15.51M
derived: sum of 3 quarters · filed 2025-08-13
-$19.87M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$20.19M
10-Q · filed 2025-05-13
-$28.33M
derived: sum of 2 quarters · filed 2025-05-13
-$32.69M
derived: sum of 3 quarters · filed 2025-05-13
-$12.62M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$48.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
-$52.88M
derived: sum of 2 quarters · filed 2025-03-11
-$32.81M
derived: sum of 3 quarters · filed 2025-03-11
-$2.58M
10-K · filed 2025-03-11
-$2.58M
10-K · filed 2024-03-08
2023-09-30-$4.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$15.71M
derived: sum of 2 quarters · filed 2024-11-12
$45.94M
10-Q · filed 2024-11-12
$45.94M
10-Q · filed 2023-11-03
$41.77M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$20.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
$50.30M
10-Q · filed 2024-08-13
$50.29M
10-Q · filed 2023-08-04
$46.13M
derived: sum of 3 quarters · filed 2024-08-13
$44.17M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$30.23M
10-Q · filed 2024-05-14
$30.23M
10-Q · filed 2023-05-05
$26.06M
derived: sum of 2 quarters · filed 2024-05-14
$24.10M
derived: sum of 3 quarters · filed 2024-05-14
-$56.58M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31-$4.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08
-$6.13M
derived: sum of 2 quarters · filed 2024-03-08
-$86.81M
derived: sum of 3 quarters · filed 2024-03-08
-$87.88M
10-K · filed 2024-03-08
2022-09-30-$1.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03
-$82.64M
derived: sum of 2 quarters · filed 2023-11-03
-$83.71M
10-Q · filed 2023-11-03
-$83.88M
derived: sum of 4 quarters · filed 2023-11-03
2022-06-30-$80.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04
-$81.75M
10-Q · filed 2023-08-04
-$81.92M
derived: sum of 3 quarters · filed 2023-08-04
-$81.98M
derived: sum of 4 quarters · filed 2023-08-04
2022-03-31-$1.08M
10-Q · filed 2023-05-05
-$1.24M
derived: sum of 2 quarters · filed 2023-05-05
-$1.30M
derived: sum of 3 quarters · filed 2023-05-05
-$2.89M
derived: sum of 4 quarters · filed 2023-05-05
2021-12-31-$161.96K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13
-$225.99K
derived: sum of 2 quarters · filed 2023-03-13
-$1.81M
derived: sum of 3 quarters · filed 2023-03-13
-$1.82M
10-K · filed 2023-03-13
2021-09-30-$64.03K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
-$1.65M
derived: sum of 2 quarters · filed 2022-11-08
-$1.66M
10-Q · filed 2022-11-08
-$1.75M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30-$1.58M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$1.60M
10-Q · filed 2022-08-09
-$1.69M
derived: sum of 3 quarters · filed 2022-08-09
-$1.72M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$11.51K
10-Q · filed 2022-05-10
-$102.00K
derived: sum of 2 quarters · filed 2022-05-10
-$140.30K
derived: sum of 3 quarters · filed 2022-05-10
$30.80M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31-$90.48K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
-$128.79K
derived: sum of 2 quarters · filed 2022-03-15
$30.81M
derived: sum of 3 quarters · filed 2022-03-15
$34.65M
10-K · filed 2022-03-15
2020-09-30-$38.30K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
$30.90M
derived: sum of 2 quarters · filed 2021-11-10
$34.74M
10-Q · filed 2021-11-10
-$270.16K
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$30.94M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
$34.78M
10-Q · filed 2021-08-16
-$231.86K
derived: sum of 3 quarters · filed 2021-08-16
-$250.44K
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31$3.84M
10-Q · filed 2021-05-13
-$31.17M
derived: sum of 2 quarters · filed 2021-05-13
-$31.19M
derived: sum of 3 quarters · filed 2021-05-13
-$26.20M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31-$35.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15
-$35.03M
derived: sum of 2 quarters · filed 2021-03-15
-$30.03M
derived: sum of 3 quarters · filed 2021-03-15
-$30.04M
10-K · filed 2021-03-15
2019-09-30-$18.58K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13
$4.98M
derived: sum of 2 quarters · filed 2020-11-13
$4.97M
10-Q · filed 2020-11-13
$21.91M
derived: sum of 4 quarters · filed 2020-11-13
2019-06-30$5.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$4.99M
10-Q · filed 2020-08-10
$21.93M
derived: sum of 3 quarters · filed 2020-08-10
$39.84M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31-$8.97K
10-Q · filed 2020-05-07
$16.93M
derived: sum of 2 quarters · filed 2020-05-07
$34.84M
derived: sum of 3 quarters · filed 2020-05-07
$39.70M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31$16.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11
$34.85M
derived: sum of 2 quarters · filed 2020-03-11
$39.71M
derived: sum of 3 quarters · filed 2020-03-11
-$5.36M
10-K · filed 2020-03-11
2018-09-30$17.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08
$22.77M
derived: sum of 2 quarters · filed 2019-11-08
-$22.31M
10-Q · filed 2019-11-08
-$22.24M
derived: sum of 4 quarters · filed 2019-11-08
2018-06-30$4.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
-$40.22M
10-Q · filed 2019-08-07
-$40.16M
derived: sum of 3 quarters · filed 2019-08-07
-$40.18M
derived: sum of 4 quarters · filed 2019-08-07
2018-03-31-$45.07M
10-Q · filed 2019-05-07
-$45.01M
derived: sum of 2 quarters · filed 2019-05-07
-$45.04M
derived: sum of 3 quarters · filed 2019-05-07
2017-12-31$61.71K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
$36.38K
derived: sum of 2 quarters · filed 2019-03-07
-$47.39K
10-K · filed 2019-03-07
2017-09-30-$25.33K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$109.09K
10-Q · filed 2018-11-08
2017-06-30-$83.76K
10-Q · filed 2018-08-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
ARVINAS, INC. (ARVN)United States$0.510B58.38
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Evolus, Inc. (EOLS)United States$0.519B-13.32
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Indaptus Therapeutics, Inc. (INDP)United States$0.537B